抗VEGFR1单克隆抗体逆转小鼠晚期糖尿病肾病
该研究在4种糖尿病肾病和慢性肾脏病小鼠模型中测试靶向VEGF-A、VEGFR2和VEGFR1的中和抗体对肾功能和組織病理的影响。结果显示,阻断VEGF-A或VEGFR2加重肾损伤,而VEGFR1选择性抗体MF1显著减少蛋白尿、改善肾功能、减轻组织学损伤并提高生存率,且延迟治疗仍可逆转已建立的病变。
要点
- 阻断VEGF-A或VEGFR2加重糖尿病小鼠肾损伤和蛋白尿。
- VEGFR1选择性抗体MF1改善多种模型肾功能、病理及生存。
- 延迟MF1治疗可逆转晚期糖尿病肾病已建立的肾脏病变。
核心结论
- 阻断VEGFR1可改善进展性慢性肾脏病模型的肾功能和微血管结构,是逆转糖尿病肾病进展的潜在新治疗策略。
研究设计与样本
- 在4种糖尿病肾病和慢性肾脏病小鼠模型中测试抗VEGF-A、抗VEGFR2和抗VEGFR1中和抗体的效果。
主要发现
- 抗VEGF-A抗体加重单肾切除糖尿病db/db小鼠的蛋白尿和肾损伤,抗VEGFR2抗体DC101结果相似。
- MF1显著降低残余肾小鼠、单肾切除db/db小鼠(伴或不伴renin-AAV注射)及eNOS-/-db/db高血压小鼠的蛋白尿,改善肾功能并减轻组织学损伤。
- MF1改善动物生存;在缺乏VEGFR1胞质酪氨酸激酶域的转基因小鼠中获益持续存在。
- 在晚期DKD的renin-AAV单肾切除db/db小鼠中,延迟MF1治疗改善生存、降低血清肌酐并逆转已建立的肾脏组织学改变。
- VEGFR1抗体增加循环PlGF和VEGF-A及肾脏VEGFR2磷酸化;MF1降低糖尿病eNOS-/-小鼠血压并急性增加db/db小鼠GFR。
临床怎么用
- VEGFR1选择性阻断可能成为逆转糖尿病肾病进展的 novel 治疗方向,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Diabetic kidney disease (DKD) continues to be the major cause of kidney failure, and its treatment is of key importance. Targeting VEGF-A has yielded conflicting results in DKD models. Here, we investigated the potential benefit of targeting VEGF-A or its receptors for the treatment of advanced mouse DKD. METHODS: Our studies tested the effects of neutralizing antibodies targeting VEGF-A, VEGFR2, and VEGFR1 on kidney function and histopathology, in 4 different mouse models of DKD and chronic kidney disease (CKD). RESULTS: Unlike previous reports, blocking VEGF-A using an anti-VEGF-A monoclonal antibody worsened albuminuria and kidney injury in uninephrectomized (unix) diabetic db/db mice. Similar results were seen with the anti-VEGFR2 antibody (DC101). In contrast, antibody MF1, a VEGFR1 selective monoclonal blocking antibody, dramatically decreased albuminuria, improved kidney function, and reduced renal histological injury in the remnant kidney mice, unix db/db mice with or without renin-AAV injection, and eNOS-/-db/db hypertensive mice. MF1 also improved animal survival. MF1 benefit persisted in albuminuric transgenic mice lacking the VEGFR1 cytoplasmic tyrosine kinase domain. In renin-AAV unix db/db mice with advanced DKD, we observed improved survival, reduced serum creatinine, and regression of established kidney histological changes following delayed MF1 treatment. VEGFR1 antibody increased circulating placental growth factor and VEGF-A as well as phosphorylation of kidney VEGFR2. MF1 reduced blood pressure in diabetic eNOS-/- mice and acutely increased the glomerular filtration rate in db/db mice. CONCLUSIONS: Our studies demonstrate that blocking VEGFR1 improved kidney function and microvascular structure in models of progressive CKD. VEGFR1 blockade provided a promising novel therapeutic approach to reverse DKD progression.
引用
- Qi Z, Tang Y, Croy JE, et al. Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody. Kidney Int. 2026. PMID: 42035988. doi:10.1016/j.kint.2026.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。